Loading: 100%
Kite Pharma, Inc. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 447 (as per Q2 2015)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker KITEno data available
Financial year endsFY ends End of no data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 17050100150200
datesClosing price (adj.)
13.10.2017179.79
11.10.2017179.79
04.10.2017179.79
27.09.2017179.68
20.09.2017179.74
13.09.2017178.99
06.09.2017178.12
30.08.2017177.90
23.08.2017138.17
16.08.2017128.09
09.08.2017120.98
02.08.2017109.42
26.07.2017111.24
19.07.2017105.43
12.07.2017104.65
05.07.2017106.50
27.06.201798.05
20.06.201791.21
13.06.201789.35
06.06.201776.64
30.05.201772.38
23.05.201770.96
16.05.201775.65
09.05.201772.10
02.05.201781.64
25.04.201780.57
18.04.201779.63
11.04.201778.29
04.04.201775.90
28.03.201778.61
21.03.201776.67
14.03.201783.89
07.03.201774.37
28.02.201770.77
21.02.201755.01
14.02.201754.54
07.02.201752.84
31.01.201750.97
24.01.201747.98
17.01.201747.46
10.01.201751.74
03.01.201745.95
27.12.201647.72
19.12.201650.63
12.12.201647.84
05.12.201653.62
28.11.201648.35
21.11.201653.68
14.11.201652.23
07.11.201645.69
31.10.201644.29
24.10.201646.21
17.10.201649.50
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
179.79n/a
Market Capitalisation
in million USD
8,822n/a
Enterprise Value
in million USD
8,244n/a
Common Shares Outstanding
as per Mar 31, 2016
49,066,715n/a
Preferred Shares Outstanding
as per Mar 31, 2016
2,000,000n/a
Average Basic Shares Outstanding
TTM
45,228,167n/a
Average Diluted Shares Outstanding
TTM
n/a
Index Membership
n/a
Business Summary
Kite Pharma Inc is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient\'s own immune system to eradicate cancer cells.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 577n/a
Receivables 0n/a
Total Current Assets 592n/a
PP&E 40n/a
Total Assets 679n/a
Accounts Payable 10n/a
Current Debt 0n/a
Total Current Liabilities 37n/a
Long-Term Debt 0n/a
Total Liabilities 90n/a
Total Equity 589n/a
Cash Flow
Depreciation & Amortisation 6n/a
Change in Working Capital -24n/a
Operating Cash Flow -98n/a
Net Change in PP&E and Intangibles -34n/a
Investing Cash Flow -268n/a
Dividends Paid 0n/a
Financing Cash Flow 281n/a
Total Change in Cash -84n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share n/a
FCF per Share n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value 0.07n/a
Other Ratios
Current Ratio 1,595.5%n/a
Liabilities to Equity Ratio 15.3%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '12FY '13FY '14FY '15
Revenue
0
0
0
17
Sales & Services Revenue
0
0
0
0
Financing Revenue
0
0
0
0
Other Revenue
0
0
0
0
Cost of revenue
0
0
0
0
Cost of Goods & Services
0
0
0
0
Cost of Financing Revenue
0
0
0
0
Cost of Other Revenue
0
0
0
0
Gross Profit
0
0
0
17
Other Operating Income
0
0
0
0
Operating Expenses
-3
-6
-37
-121
Selling, General & Administrative
-1
-1
-14
-44
Selling & Marketing
0
0
0
0
General & Administrative
0
0
0
0
Research & Development
-2
-5
-23
-76
Depreciation & Amortization
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
Other Operating Expense
0
0
0
0
Operating Income (Loss)
-3
-6
-37
-103
Non-Operating Income (Loss)
0
0
7
3
Interest Expense, net
0
0
7
2
Interest Expense
0
0
0
0
Interest Income
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
Other Non-Operating Income (Loss)
0
0
0
1
Pretax Income (Loss), Adjusted
-3
-6
-30
-100
Abnormal Gains (Losses)
0
0
0
0
Acquired In-Process R&D
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
Abnormal Derivatives
0
0
0
0
Disposal of Assets
0
0
0
0
Early extinguishment of Debt
0
0
0
0
Asset Write-Down
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
Sale of Business
0
0
0
0
Legal Settlement
0
0
0
0
Restructuring Charges
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
Insurance Settlement
0
0
0
0
Other Abnormal Items
0
0
0
0
Pretax Income (Loss)
-3
-6
-30
-100
Income Tax (Expense) Benefit, net
0
0
0
0
Current Income Tax
0
0
0
0
Deferred Income Tax
0
0
0
0
Tax Allowance/Credit
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
Income (Loss) from Continuing Operations
-3
-6
-30
-100
Net Extraordinary Gains (Losses)
0
0
0
0
Discontinued Operations
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
Income (Loss) Including Minority Interest
-3
-6
-30
-100
Minority Interest
0
0
0
0
Net Income
-3
-6
-30
-100
Preferred Dividends
0
1
1
0
Other Adjustments
0
0
0
0
Net Income Available to Common Shareholders
-3
-5
-29
-100
Remarks
restated on Mar 26, 2015 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
Balance SheetBS data quality: 94% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '12FY '13FY '14FY '15
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
22
367
615
Cash & Cash Equivalents
n/a
22
209
393
Short Term Investments
n/a
0
158
222
Accounts & Notes Receivable
n/a
0
0
0
Accounts Receivable, Net
n/a
0
0
0
Notes Receivable, Net
n/a
0
0
0
Unbilled Revenues
n/a
0
0
0
Inventories
n/a
0
0
0
Raw Materials
n/a
0
0
0
Work In Process
n/a
0
0
0
Finished Goods
n/a
0
0
0
Other Inventory
n/a
0
0
0
Other Short Term Assets
n/a
0
1
16
Prepaid Expenses
n/a
0
1
16
Derivative & Hedging Assets
n/a
0
0
0
Assets Held-for-Sale
n/a
0
0
0
Deferred Tax Assets
n/a
0
0
0
Income Taxes Receivable
n/a
0
0
0
Discontinued Operations
n/a
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
Total Current Assets
n/a
23
368
631
Property, Plant & Equipment, Net
n/a
0
2
30
Property, Plant & Equipment
n/a
0
0
0
Accumulated Depreciation
n/a
0
0
0
Long Term Investments & Receivables
n/a
0
0
0
Long Term Investments
n/a
0
0
0
Long Term Marketable Securities
n/a
0
0
0
Long Term Receivables
n/a
0
0
0
Other Long Term Assets
n/a
0
0
47
Intangible Assets
n/a
0
0
11
Goodwill
n/a
0
0
25
Other Intangible Assets
n/a
0
0
0
Prepaid Expense
n/a
0
0
0
Deferred Tax Assets
n/a
0
0
0
Derivative & Hedging Assets
n/a
0
0
0
Prepaid Pension Costs
n/a
0
0
0
Discontinued Operations
n/a
0
0
0
Investments in Affiliates
n/a
0
0
0
Miscellaneous Long Term Assets
n/a
0
0
10
Total Noncurrent Assets
n/a
0
2
77
Total Assets
n/a
23
371
708
Liabilities and owners' equity
Payables & Accruals
n/a
1 1362000
7 6725000
20 19836000
Accounts Payable
n/a
0 382000
2 2320000
8 8049000
Accrued Taxes
n/a
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
Other Payables & Accruals
n/a
1 980000
4 4405000
12 11787000
Short Term Debt
n/a
0 0
0 0
0 0
Short Term Borrowings
n/a
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
Other Short Term Liabilities
n/a
0 0
0 0
16 16333000
Deferred Revenue
n/a
0 0
0 0
16 16333000
Derivatives & Hedging
n/a
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
0 0
0 0
Total Current Liabilities
n/a
1 1362000
7 6725000
36 36169000
Long Term Debt
n/a
0 0
0 0
0 0
Long Term Borrowings
n/a
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
Other Long Term Liabilities
n/a
0 39000
1 1439000
56 56034000
Accrued Liabilities
n/a
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
Deferred Revenue
n/a
0 0
0 0
32 32176000
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
0 39000
1 1439000
24 23858000
Total Noncurrent Liabilities
n/a
0 39000
1 1439000
56 56034000
Total Liabilities
n/a
1 1401000
8 8164000
92 92203000
Preferred Equity
n/a
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
37 36996000
421 420890000
776 775637000
Common Stock
n/a
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
Treasury Stock
n/a
0 0
0 0
0 0
Retained Earnings
n/a
-15 -15435000
-58 -58004000
-160 -159657000
Other Equity
n/a
0 0
0 -297000
0 -220000
Equity Before Minority Interest
n/a
22 21561000
363 362589000
616 615760000
Minority Interest
n/a
0 0
0 0
0 0
Total Equity
n/a
22 21561000
363 362589000
616 615760000
Total Liabilities & Equity
n/a
23 22962000
371 370753000
708 707963000
Remarks restated on n/a restated on Mar 26, 2015 n/a restated on Feb 29, 2016 n/a restated on May 9, 2016 n/a
Cash Flow StatementCF data quality: 92% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '12FY '13FY '14FY '15
Net Income/Starting Line
-3
-6
-43
-102
Net Income
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
Other Adjustments
0
0
0
0
Depreciation & Amortization
0
0
0
5
Non-Cash Items
0
0
22
42
Stock-Based Compensation
0
0
0
0
Deferred Income Taxes
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
Change in Working Capital
0
1
3
39
(Increase) Decrease in Accounts Receivable
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
Cash from Operating Activities
-3
-6
-17
-16
Change in Fixed Assets & Intangibles
0
0
-2
-27
Disposition of Fixed Assets & Intangibles
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
Net Change in Long Term Investment
0
0
-158
-65
Decrease in Long Term Investment
0
0
0
0
Increase in Long Term Investment
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
0
-15
Net Cash from Divestitures
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
Cash for Joint Ventures
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
Other Investing Activities
0
0
0
-2
Net Cash From Discontinued Operations (investing)
0
0
0
0
Cash from Investing Activities
0
0
-160
-108
Dividends Paid
0
0
0
0
Cash From (Repayment of) Debt
0
0
50
0
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
Cash From Long Term Debt
0
0
0
0
Cash From (Repurchase of) Equity
0
20
338
308
Increase in Capital Stock
0
20
338
308
Decrease in Capital Stock
0
0
0
0
Other Financing Activities
0
0
-24
0
Net Cash From Discontinued Operations (financing)
0
0
0
0
Cash from Financing Activities
0
20
364
308
Net Cash Before Disc. Operations and FX
-3
14
187
183
Change in Cash from Disc. Operations and Other
0
0
0
0
Net Cash Before FX
-3
14
187
183
Effect of Foreign Exchange Rates
0
0
0
0
Net Changes in Cash
-3
14
187
184
Remarks
restated on Mar 26, 2015 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo